Halozyme Therapeutics, Inc. is a U.S.-based biopharmaceutical technology company focused on improving the delivery of injectable medicines. Its core ENHANZE drug delivery platform uses a proprietary recombinant human hyaluronidase (rHuPH20) to temporarily modify the subcutaneous space, enabling rapid, large‑volume subcutaneous administration of biologics that are often delivered intravenously.
Halozyme collaborates with global pharmaceutical companies to develop subcutaneous formulations across oncology, immunology, and other therapeutic areas, generating revenue through upfront payments, milestones, and royalties on partnered products. The company also supplies hyaluronidase-based products to support patient-friendly administration approaches. Halozyme is headquartered in San Diego, California.
